Limited use for dual treatment with boosted protease inhibitors plus lamivudine in first-line antiretroviral therapy

Lancet Infect Dis. 2015 Jul;15(7):748-9. doi: 10.1016/S1473-3099(15)00098-5. Epub 2015 Jun 7.

Authors

Catherine Orrell¹, Richard Kaplan²

Affiliations

¹ Desmond Tutu HIV Foundation, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa. Electronic address: [email protected].
² Desmond Tutu HIV Foundation, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa.

PMID: 26062879
DOI: 10.1016/S1473-3099(15)00098-5

No abstract available

Publication types

Comment

MeSH terms

Anti-HIV Agents / therapeutic use*
Female
HIV Infections / drug therapy*
HIV Protease Inhibitors / therapeutic use*
HIV-1*
Humans
Male
RNA, Viral / blood*
Reverse Transcriptase Inhibitors / therapeutic use*

Substances

Anti-HIV Agents
HIV Protease Inhibitors
RNA, Viral
Reverse Transcriptase Inhibitors